论文部分内容阅读
目的探讨变应性鼻炎舌下含服粉尘螨滴剂免疫治疗早期鼻分泌物嗜酸细胞计数及与临床症状的关系。方法对43例行舌下含服粉尘螨滴剂免疫治疗的变应性鼻炎患者,在免疫治疗前及治疗后2、4、8周采集鼻腔分泌物,经涂片染色后计数鼻分泌物嗜酸细胞,并分析其与临床症状的可能相关性。结果舌下含服粉尘螨滴剂免疫治疗后4、8周鼻分泌物嗜酸细胞计数较免疫治疗前下降,差异有统计学意义(P<0.05);免疫治疗后4周及8周主观症状有明显改善的患者鼻分泌物嗜酸细胞计数较免疫治疗前下降,差异有统计学意义(P<0.05)。结论舌下含服粉尘螨滴剂治疗变应性鼻炎时,鼻黏膜局部免疫状态的改变在免疫治疗后4周或更早的时间已经发生。
Objective To investigate the relationship between nasal discharge eosinophil count and clinical symptoms in patients with allergic rhinitis treated with drops of dust mites. Methods Nasopharyngeal secretions were collected before immunotherapy and at 2, 4, and 8 weeks after treatment in 43 sublingual immunotherapy with dust mites. Nasal secretion was counted after smear staining Acid cells, and analyze their possible correlation with clinical symptoms. Results The numbers of nasal eosinophils in nasal secretions decreased 4 and 8 weeks after immunotherapy. The difference was statistically significant (P <0.05). Subjective symptoms at 4 and 8 weeks after immunotherapy Patients with significantly improved nasal secretions eosinophil count than before immunotherapy decreased, the difference was statistically significant (P <0.05). Conclusions When sublingual d.citralid drops are administered to treat allergic rhinitis, changes in nasal mucosal local immune status have occurred 4 weeks or more after immunotherapy.